Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.24 USD

72.24
3,014,315

-1.43 (-1.94%)

Updated Aug 27, 2024 03:59 PM ET

After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.

Why DexCom (DXCM) Dipped More Than Broader Market Today

by Zacks Equity Research

DexCom (DXCM) reachead $122.59 at the closing of the latest trading day, reflecting a -0.41% change compared to its last close.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Neogen (NEOG) to Advance Feline DNA Testing With New Pact

by Zacks Equity Research

Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger

by Zacks Equity Research

Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.

Align Technologies (ALGN) Secures Updated Medical Device License

by Zacks Equity Research

Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.

Here's Why You Should Buy Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.

Tandem Diabetes (TNDM) Avails Tandem Source in the United States

by Zacks Equity Research

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Integra (IART) to Advance ENT Division With New Buyout Deal

by Zacks Equity Research

Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Medtronic (MDT) Expands AI-Driven Care With New Partnership

by Zacks Equity Research

Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

by Zacks Equity Research

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

by Zacks Equity Research

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.